Agreement signedAgreed 18 Jun 2023
Eli Lilly and Company /
DICE Therapeutics Inc.
Eli Lilly and Company agrees to buy DICE Therapeutics Inc.
01 / BuyerEli Lilly and Company
02 / TargetDICE Therapeutics Inc.
What happened
Eli Lilly and Company agreed to acquire DICE Therapeutics Inc. for $48.00 per Share, according to a filing dated Aug. 9, 2023.
Who is involved, and the source
Everything on this page comes from the source below.
Advisers
Target
- Fairness opinion to the targetCenterviewAdviser profile
Advisers are not parties to the deal.
01
Source · Original source
Eli Lilly and Company agrees to buy DICE Therapeutics Inc.
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Announced
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly